These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. Boesen MS; Jensen PEH; Magyari M; Born AP; Uldall PV; Blinkenberg M; Sellebjerg F Mult Scler Relat Disord; 2018 Aug; 24():175-183. PubMed ID: 30055504 [TBL] [Abstract][Full Text] [Related]
4. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Thouvenot E; Hinsinger G; Demattei C; Uygunoglu U; Castelnovo G; Pittion-Vouyovitch S; Okuda D; Kantarci O; Pelletier D; Lehmann S; Marin P; Siva A; Lebrun C Mult Scler; 2019 Apr; 25(5):669-677. PubMed ID: 29564952 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Comabella M; Fernández M; Martin R; Rivera-Vallvé S; Borrás E; Chiva C; Julià E; Rovira A; Cantó E; Alvarez-Cermeño JC; Villar LM; Tintoré M; Montalban X Brain; 2010 Apr; 133(Pt 4):1082-93. PubMed ID: 20237129 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762 [TBL] [Abstract][Full Text] [Related]
10. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960 [TBL] [Abstract][Full Text] [Related]
11. Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Muñoz-San Martín M; Torras S; Robles-Cedeño R; Buxó M; Gomez I; Matute-Blanch C; Comabella M; Villar LM; Perkal H; Quintana E; Ramió-Torrentà L Epigenomics; 2020 Dec; 12(23):2065-2076. PubMed ID: 33290101 [No Abstract] [Full Text] [Related]
12. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Quintana E; Coll C; Salavedra-Pont J; Muñoz-San Martín M; Robles-Cedeño R; Tomàs-Roig J; Buxó M; Matute-Blanch C; Villar LM; Montalban X; Comabella M; Perkal H; Gich J; Ramió-Torrentà L Eur J Neurol; 2018 Sep; 25(9):1189-1191. PubMed ID: 29797629 [TBL] [Abstract][Full Text] [Related]
13. Neurofilament light chain level is a weak risk factor for the development of MS. Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M Neurology; 2016 Sep; 87(11):1076-84. PubMed ID: 27521440 [TBL] [Abstract][Full Text] [Related]
14. The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. Schwenkenbecher P; Konen FF; Wurster U; Jendretzky KF; Gingele S; Sühs KW; Pul R; Witte T; Stangel M; Skripuletz T Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30501024 [TBL] [Abstract][Full Text] [Related]
15. The Cerebrospinal Fluid in Multiple Sclerosis. Deisenhammer F; Zetterberg H; Fitzner B; Zettl UK Front Immunol; 2019; 10():726. PubMed ID: 31031747 [TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of prognostic biomarkers in optic neuritis. Tejeda-Velarde A; Costa-Frossard L; Sainz de la Maza S; Carrasco Á; Espiño M; Picón C; Toboso I; Walo PE; Lourido D; Muriel A; Álvarez-Cermeño JC; Villar LM Eur J Neurol; 2018 Apr; 25(4):614-618. PubMed ID: 29272057 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. Møllgaard M; Degn M; Sellebjerg F; Frederiksen JL; Modvig S Eur J Neurol; 2016 May; 23(5):898-905. PubMed ID: 26872061 [TBL] [Abstract][Full Text] [Related]
18. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Tintore M; Rovira À; Río J; Otero-Romero S; Arrambide G; Tur C; Comabella M; Nos C; Arévalo MJ; Negrotto L; Galán I; Vidal-Jordana A; Castilló J; Palavra F; Simon E; Mitjana R; Auger C; Sastre-Garriga J; Montalban X Brain; 2015 Jul; 138(Pt 7):1863-74. PubMed ID: 25902415 [TBL] [Abstract][Full Text] [Related]